Global Cardiovascular Disease Drugs Market Future Outlook, Market Analysis - Ken Research - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Global Cardiovascular Disease Drugs Market Future Outlook, Market Analysis - Ken Research

Description:

The Cardiovascular Disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia, which accelerate the development of atherosclerotic plaque build up within blood vessels. For more information on the research report, refer to below link:- – PowerPoint PPT presentation

Number of Views:12
Slides: 8
Provided by: kenresearch6
Category: Other

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Global Cardiovascular Disease Drugs Market Future Outlook, Market Analysis - Ken Research


1
Global Cardiovascular Disease Drugs Market To
2023- Ken Research
2
The Cardiovascular Disease (CVD) therapy area
encompasses a range of different diseases and
conditions affecting the heart and/or blood
vessels. The most crucial risk factors for CVD
are hypertension and dyslipidemia, which
accelerate the development of atherosclerotic
plaque build up within blood vessels. As atheroma
develops it causes the affected blood vessels to
narrow, restricting blood flow to the body, brain
or heart, depending on its locale. It is also
possible for the fibrous cap of this plaque to
break off, triggering the coagulation cascade and
causing a thrombus to form locally, which can
completely occlude blood flow. The treatments of
CVD typically focus on prevention by controlling
risk factors. As such, the treatments usually
fall within three categories Anti-hypertensives,
which aim to maintain blood pressure within a
normal range anti-dyslipidemic drugs, which aim
to modify lipid levels to a normal range and
anti-thrombotic drugs, which aim to prevent
thrombi formation by inhibiting the coagulation
cascade or platelet aggregation. There has been
vast scientific innovation in the CVD
therapeutics market in recent decades,
particularly within the anti-dyslipidemia market.
This was seen first with the introduction of
statins such as Lipitor (atorvastatin) and more
recently with the introduction of protein
convertase subtilisin/kexin type 9 (PCSK9)
inhibitors. However, other areas such as the
heart failure market remain poorly treated.
3
Dyslipidemia and hypertension have continuing
high levels of development within the current
pipeline and, despite high levels of generic
development, there is also a large degree of
innovation, with targets such as apolipoproteins
and elements of the reverse lipid transport
pathway. In addition, the current pipeline
includes nearly 200 products for the treatment of
heart failure, suggesting an increase in interest
in treating the disease. With over 1,400
products in active development, the pipeline for
CVD is extensive. Does current pipeline
innovation hold the potential to change the CVD
market in the near future? The clinical trials
process for CVD drugs is complex. What is the
risk of a CVD drug failing to reach the market?
What is the risk of a drug failing at a specific
Phase? The CVD market landscape is forecast to
undergo a period of substantial change following
key approvals, patent expiries and acquisitions.
Which of the leading companies will have the
highest market share by 2023? What strategies
have these companies adopted to achieve market
growth? There has been a moderately high level of
deal activity in recent years. How do deal
frequency and value compare between target
families and molecule types? Understand the
current clinical and commercial landscape through
a comprehensive analysis of disease symptoms,
diagnostic methods, etiology, pathophysiology,
comorbidities and complications, epidemiology,
prognosis and treatment.
4
Recognize the leading therapeutics, as well as
gaps in the market, with portfolios of key
marketed products, including historical and
forecast sales revenue patterns. Identify trends
and developments, in terms of molecule type and
molecular target, within the overall CVD
pipeline, as well as for key CVD indications
hypertension, heart failure, dyslipidemia and
thrombotic events. Consider market opportunities
and potential risks by examining trends in
clinical trial duration and size, as well as
clinical trial failure rates, by stage of
development, key indication, molecule type and
molecular target. Predict how the evolving
treatment landscape will drive market growth to
2023 and understand the contributions that
different products and companies will make to
this growth. Understand how strategic
consolidations have shaped the current pipeline
and marketed products landscape. Key Topics
Covered in the Report- Global Cardiovascular
Disease Drugs Market Research Report Global
Cardiovascular Disease Drugs Market
Forecast Global Cardiovascular Disease Drugs
Market Revenue Global Cardiovascular Disease
Drugs Market Size Global Cardiovascular Disease
Drugs Market Future Outlook Global Cardiovascular
Disease Drugs Market Analysis
5
Global Cardiovascular Disease Drugs Market
Opportunities Global Cardiovascular Disease Drugs
Market Competition Global Cardiovascular Disease
Drugs Market Trends Global Cardiovascular Disease
Drugs Market Shares Global Cardiovascular Disease
Drugs Market Growth Analysis Global
Cardiovascular Disease Drugs Market   For more
information on the research report, refer to
below link- https//www.kenresearch.com/healthcar
e/pharmaceuticals/global-cardiovascular-disease-dr
ugs-market-to-2023/142623-91.html Related
Reports by Ken Research- https//www.kenresearch.
com/healthcare/pharmaceuticals/global-diabetes-dru
gs-market/142343-91.html   https//www.kenresearch
.com/healthcare/pharmaceuticals/global-dermatology
-drugs-market-to-2023/138233-91.html
6
Contact Us- Ken ResearchAnkur Gupta, Head
Marketing CommunicationsSales_at_kenresearch.com
91-124 423 0204
7
(No Transcript)
About PowerShow.com